FDA sends Bausch & Lomb warning letter; Lonza picked to manufacture stems cells;

> Bausch & Lomb has received a warning letter from the FDA saying that 6 dilutions of pilocarpine hydrochloride ophthalmic solutions should be treated as prescription drugs. Letter

> The European Medicines Agency (EMA) has issued new guidance to drug manufacturers of slow release oral and patch products on what it expects them to do to show that "the prolonged release product maintains its drug release characteristics regardless of relevant variability in physiological conditions." Story

> Lonza has received a $9.5 million grant from the National Institutes of Health to provide GMP manufacturing of induced pluripotent stem cells (iPSCs) and clinical-grade iPSC-derived cell types. Item

> Hungarian drug developer Genetic Immunity has gotten approval from regulators there for a manufacturing facility in Budapest for clinical trials material and eventually for commercial production. Release

And Finally... A joint event between CPhI and a Russian pharma group will be held in April in St. Petersburg, Russia. Item

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.